Literature DB >> 17509386

Impact of obesity and bariatric surgery on cardiovascular disease.

Michael A Mathier1, Ramesh C Ramanathan.   

Abstract

Morbid obesity is a growing public health concern with multiple associated cardiovascular comorbidities. Bariatric surgery has emerged as a safe and effective treatment for morbidly obese patients at risk for, or already suffering from, cardiovascular disease. Weight loss induced by the surgery has been shown to improve cardiovascular risk factors, cardiac structure and function, and the clinical course of established cardiovascular disease. The role of adipocyte-derived cytokines in mediating cardiovascular pathophysiology in obesity-and its modulation after weight loss-is under active investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17509386     DOI: 10.1016/j.mcna.2007.02.002

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  10 in total

Review 1.  The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity.

Authors:  Christopher N Ochner; Charlisa Gibson; Susan Carnell; Carl Dambkowski; Allan Geliebter
Journal:  Physiol Behav       Date:  2010-05-08

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

Review 3.  Adaptation and maladaptation of the heart in obesity.

Authors:  Romain Harmancey; Christopher R Wilson; Heinrich Taegtmeyer
Journal:  Hypertension       Date:  2008-06-23       Impact factor: 10.190

4.  Physical fitness in morbidly obese patients: effect of gastric bypass surgery and exercise training.

Authors:  Sanne Stegen; Wim Derave; Patrick Calders; Christophe Van Laethem; Piet Pattyn
Journal:  Obes Surg       Date:  2009-12-09       Impact factor: 4.129

5.  Progressive regression of left ventricular hypertrophy two years after bariatric surgery.

Authors:  Mohamed F Algahim; Thomas R Lux; Joshua G Leichman; Anthony F Boyer; Charles C Miller; Susan T Laing; Erik B Wilson; Terry Scarborough; Sherman Yu; Brad Snyder; Carol Wolin-Riklin; Ursula G Kyle; Heinrich Taegtmeyer
Journal:  Am J Med       Date:  2010-06       Impact factor: 4.965

Review 6.  Obesity and metabolic syndrome in kidney transplantation.

Authors:  Heather LaGuardia; Rubin Zhang
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

7.  Obesity and vascular dysfunction.

Authors:  Phoebe A Stapleton; Milinda E James; Adam G Goodwill; Jefferson C Frisbee
Journal:  Pathophysiology       Date:  2008-06-20

8.  Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass.

Authors:  Victoria Catalán; Javier Gómez-Ambrosi; Beatriz Ramirez; Fernando Rotellar; Carlos Pastor; Camilo Silva; Amaia Rodríguez; María J Gil; Javier A Cienfuegos; Gema Frühbeck
Journal:  Obes Surg       Date:  2007-11       Impact factor: 4.129

9.  Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery.

Authors:  Michael A Trakhtenbroit; Joshua G Leichman; Mohamed F Algahim; Charles C Miller; Frank G Moody; Thomas R Lux; Heinrich Taegtmeyer
Journal:  Am J Med       Date:  2009-05       Impact factor: 4.965

10.  Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients.

Authors:  Anna Katharine Hindle; Claire Edwards; Alisha Mendonsa; Marcos Rojkind; Tim McCaffrey; Sidney Fu; Fred Brody
Journal:  Surg Endosc       Date:  2009-12-30       Impact factor: 4.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.